Debt Ceiling Discussions Consider Cuts to Biologics Reimbursement: Take Action!
July 14, 2011
Congressional leadership and the White House are actively discussing Medicare spending reductions in the debt ceiling debate. Among the list of potential reductions is a cut in the Medicare reimbursement for biologics.
Biologics are already reimbursed at artificially low rates under Medicare due to prompt-pay discounts that are included in the average sale price calculation. Further reductions in reimbursement will cause additional financial burdens to practicing rheumatologists and will impact patient access to these necessary drug therapies.
Contact your Senators and Representative, the White House Today!
For Congress, please use the AMA's Grassroots Hotline at (800) 833-6354
For the White House, please use (202) 456-1111.
